Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 812345...Last »

Company founded by Shkreli off the hook in $43 million lawsuit: judge

Vyera Pharmaceuticals – formerly known as Turing Pharmaceuticals – does not have to pay Impax Laboratories $43 million in a dispute stemming from Turing founder Martin Shkreli’s decision to boost by 5,000 percent the price of a drug Turing bought from Impax, a U.S. judge ruled.

Read More »

U.S. invests in late-stage Ebola vaccines, drugs

The U.S. government is investing more than $170 million to help two new vaccines against Ebola and two Ebola drugs complete the steps needed for FDA approval.

Read More »

Stopping aspirin therapy may raise heart attack, stroke risk

Stopping low-dose aspirin therapy without good reason raises the likelihood of heart attack or stroke by nearly 40 percent, a large Swedish study suggests.

Read More »

FDA approves fast-acting insulin Fiasp

The U.S. Food and Drug Administration approved Novo Nordisk’s fast-acting insulin to treat diabetes.

Read More »

Bay Area’s Zogenix Explodes on Late-Stage Epilepsy Data

Shares of Zogenix Inc. more than doubled following the company’s announcement that its investigational Dravet syndrome drug met its primary endpoints in cutting seizure rates in juvenile patients.

Read More »

Almirall Discontinues R&D for Two Drugs in the U.S.

Almirall SA announced it plans to halt all research into P3058 (onychomycosis) and P3073 (nail psoriasis) in the U.S. However, clinical trials planned in Europe will continue as scheduled.

Read More »

Merck & Co. Terminates Hep C Development Programs

Following a review of Phase II efficacy data and a scan of the “evolving marketplace,” Merck & Co. announced that the company was terminating two hepatitis C programs.

Read More »

Roche’s Perjeta regimen gets FDA priority review

The U.S. FDA granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery.

Read More »

Eli Lilly wins U.S. approval for breast cancer drug

The U.S. Food and Drug Administration approved an Eli Lilly and Co. drug to treat advanced breast cancer that has progressed following prior treatment.

Read More »

Senators want probe of Allergan transfer deal with tribe: letter

Four U.S. senators have asked the Senate Judiciary Committee to launch an investigation into a deal drugmaker Allergan struck with a Native American tribe to protect some of its patents from generic challenge, according to a letter seen by Reuters.

Read More »

CSL hemophilia A drug approved in Japan

Global biotherapeutics leader CSL Behring announced that Japan’s Ministry of Health, Labor and Welfare approved Afstyla [lonoctocog alfa] for hemophilia A.

Read More »

AbbVie, Amgen resolve Humira patent disputes

AbbVie announced today a global resolution of all intellectual property-related litigation with Amgen over Amgen’s proposed biosimilar adalimumab product.

Read More »

Abiomed invests in Israeli medical device maker Magenta

Israeli medical device company Magenta Medical said it has raised $15 million in funding led by Massachusetts-based Abiomed Inc., a maker of catheter-based heart pumps, and venture capital firm Pitango.

Read More »

EDC Database Development Often Leads to Clinical Trial Delays, Study Shows

It has long been thought that electronic data collection, also known as EDC, would be a time-saver when it comes to running clinical trials. But that may not be the case, according to a joint study released by Tufts University and Veeva Systems.

Read More »

EU approves Sanofi and Regeneron’s dupilumab in eczema

The European Commission approved Regeneron Pharmaceuticals’ and Sanofi’s key biologic treatment dupilumab for moderate-to-severe atopic dermatitis, the two companies said.

Read More »

Novartis forges UC Berkeley pact, sees drug hopefuls in three years

Novartis’ research head expects an alliance with a University of California chemistry lab to produce drug candidates within three years as the Swiss company accelerates its hunt for new medicines.

Read More »

Mateon Therapeutics Cuts 60 Percent of Jobs

Following a failure to determine clear efficacy in its experimental combo ovarian cancer drug, Mateon ended the drug program and cut 60% of its employees.

Read More »

Ex-Biotech Analyst Charged With Insider Trading

The U.S. Attorney’s Office in Chicago charged a former Zacks biotech analyst with securities fraud over allegations of insider trading.

Read More »

EU drugs watchdog staff favor move to Amsterdam: sources

Picking Amsterdam, Barcelona or Vienna as the new headquarters of Europe’s drugs regulator after Brexit would be the best option for retaining staff, according to a survey of its workers.

Read More »

Republicans fail again to kill off Obamacare in Senate

U.S. Republicans fell short yet again in their seven-year drive to repeal Obamacare, in a bitter defeat that raises more questions about their ability to enact President Donald Trump’s agenda.

Read More »

Page 1 of 812345...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom